Samsung Bioepis Urges FDA to Reconsider Necessity of Comparative Efficacy Studies in Biosimilar Approval
2026-02-02
PubComNonGov2026-02-02
Carter Struck
WASHINGTON, Feb. 2 -- Samsung Bioepis has submitted a public comment letter to the Food and Drug Administration (FDA), advocating for a reevaluation of the need for Comparative Efficacy Studies (CES) . . .
TARGETED NEWS SERVICE (founded 2004) features non-partisan 'edited journalism' news briefs and information for news organizations, public policy groups and individuals; as well as 'gathered' public policy information, including news releases, reports, speeches. For more information contact MYRON STRUCK, editor, editor@targetednews.com, Springfield, Virginia; 703/304-1897; https://targetednews.com
WASHINGTON, Feb. 2 -- Samsung Bioepis has submitted a public comment letter to the Food and Drug Administration (FDA), advocating for a reevaluation of the need for Comparative Efficacy Studies (CES) . . .
TARGETED NEWS SERVICE (founded 2004) features non-partisan 'edited journalism' news briefs and information for news organizations, public policy groups and individuals; as well as 'gathered' public policy information, including news releases, reports, speeches. For more information contact MYRON STRUCK, editor, editor@targetednews.com, Springfield, Virginia; 703/304-1897; https://targetednews.com
Copyright © Targeted News Service, 2026